PerpEquities

Equity

Innovent Biologics, Inc. (INNOVENT) perpetual futures

INNOVENT perpetual futures on 1 crypto exchange – live perp price vs the stock, funding rate, open interest and where to trade INNOVENTUSDT.

Innovent Biologics is a Chinese biopharmaceutical company that discovers, develops and manufactures antibody drug candidates for oncology, ophthalmology, immunology and metabolic diseases, with products such as Tyvyt (sintilimab).

$10.78-0.1%
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

venue perp mark · MEXC (INNOVENT/USDT)
Auto: highest-volume live perp venue

Trading data

Perpetual market activity

1/1 live markets
Venues
1
Live markets
1/1
24h volume
$101K
Open interest
$801.6
Best liquidity
$662.2
MEXC
Tightest spread
+55.6 bps
MEXC
Highest volume
$101K
MEXC
Settlement mix
USDT · 1/1
Perp/spot vol.
0.00x
Spot volume $72.2M
OI / float
0.00%
Float $16.9B
Spot performance
1D-2.70%
5D-2.59%
1M-3.42%
6M+3.35%
YTD+11.15%
1Y-6.66%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
MEXCTradeINNOVENT/USDTTrading$10.78-21.9% APR
-0.020% every 8h		+55.6 bps$662.2$101K$801.6USDT20x

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 1 venues absorb $10k

Too thin: MEXC

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

INNOVENT
MEXC · INNOVENT/USDT$662.2

Tightest spread

INNOVENT
MEXC · INNOVENT/USDT+55.6 bps

Highest volume

INNOVENT
MEXC · INNOVENT/USDT$101K

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q2 '26 · filed 2026-06-30 · next report 2027-03-31 · Updated 38m ago
All financials →

Valuation & key figures

Market cap
$18.8B
Updated 38m ago
Revenue
CN¥15.6B
Trailing 12 months
Revenue growth
+46%
FY2026 consensus
Profit margin
7.8%
Net income / revenue, TTM
P/E
101.8×
P/S
8.1×
Price / sales, TTM
Peer P/E
17.2×
Similar listed perps
EV / EBITDA
43.6×
TTM
Free cash flow
CN¥13B
Trailing 12 months
Net income
CN¥1.22B
Trailing 12 months
Revenue estimate
CN¥19B
FY2026 consensus
Earnings
2027-03-31
Revenue est. $1.6B · Updated 38m ago
Dividend
–
No dividend
Revenue (TTM)CN¥15.6B+36.5% vs a year agoLast 2 half-years; bars = each half-year
Operating margin (TTM)12.0%+5.7 pp vs a year agoOperating income CN¥1.87B
Net income (TTM)CN¥1.22B+7.3% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)CN¥13B+698.4% vs a year agoCapex CN¥398M
Diluted EPS (TTM)CN¥0.67-0.3% vs a year agoSum of the last 2 half-years
Net cashCN¥17.7B+186.9% vs a year agoCash + short-term investments - debt
  • Revenue growth slowing: 42.8% year on yearQ2 '26 revenue CN¥8.5B, against an average of 45.6% over the four half-years before.
  • Operating margin 12.0% (TTM), +5.7 pp on a year agoOperating income grew 157.7% while revenue grew 36.5%.
  • 22.3% of pre-tax profit is eaten by non-operating lossesPre-tax income CN¥1.53B vs operating income CN¥1.87B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.
  • Capex 2.6% of revenue (a year ago 2.7%)CN¥398M invested in the last 2 half-years (+29.3% on a year earlier). Free cash flow CN¥13B = 1,070.3% of net income.

Revenue, operating income and growth

quarterly
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates

Next catalyst

Catalysts

Earnings
2027-03-31
Revenue est. $1.6B · Updated 38m ago

No unusual perp activity right now.

Reference data

Market context

Reference market

Closed
Hong Kong Stock Exchange
Regular hours
CLOSED – CLOSED GMT+8
Next holiday
Dec 24, 2026 · Christmas Eve (half day)

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 20260.21$2.8B+46%19
FY 20270.33$3.6B+25%20
FY 20280.45$4.2B+18%24
FY 20290.68$5.3B+25%21
FY 20301.09$5.8B+10%13
Q4 20260.17$1.6B+53%1
Source: FMP · Consensus

Company events

6
2027-03-31EarningsActual - / Estimate 1.31-
2026-08-25EarningsActual 0.808 / Estimate 0.542Beat
2026-03-26EarningsActual -0.0112 / Estimate 0.134Miss
2025-08-26EarningsActual 0.555 / Estimate 0.196Beat
2025-03-26EarningsActual 0.194 / Estimate -0.245Beat
2024-08-28EarningsActual -0.257 / Estimate -0.268Beat

Peer comparison

Similar listed perps
NameMarket capP/SP/EProfit marginVenues
TSCO$18.9B1.219.6+6.1%1NAVER$18.7B1.915.4+12.8%15RDDT$19B6.219.0+32.1%19CHTR$18.7B0.313.8+2.5%1NANYAPCB$19.2B12.178.2+15.4%1GEELY$18.4B0.37.4+4.5%1FTAI$18.4B5.436.0+15.5%2FSLR$18.4B3.79.9+37.1%3

Company data

Company intelligence

Updated: Nov 15, 2026, 07:28 AM UTC

Company profile

Sector
Healthcare
Industry
Biotechnology
Chief executive
De-Chao Yu
Employees
8,754
IPO date
Oct 31, 2018
Country
CN
Exchange
Hong Kong Stock Exchange
Website
Altman Z-scorei3.93
Piotroski scorei7/9
Overall ratingiC+
Owner earningsiCN¥5.19BCN¥2.88 per share

Rating factors

Return on equityi
3/5
Return on assetsi
3/5
Debt to equityi
3/5
Price to earningsi
1/5
Price to booki
1/5
Market cap history
HK$146.28B-10.4%Aug 2026 – Nov 2026
HK$139.20BHK$159.18BHK$179.16BHigh: HK$179.16B · 2026-08-31Low: HK$139.20B · 2026-11-02Latest: HK$146.28B · 2026-11-13Aug 2026Sep 2026Oct 2026Nov 2026
Latest: HK$146.28B · 2026-11-13High: HK$179.16B · 2026-08-31Low: HK$139.20B · 2026-11-02
Largest fund holders
FundWeightShares held
VXUS0.04%24M
VWO0.17%22.9M
IEMG0.11%16.5M
2800.HK0.85%13M
VWIGX0.34%11.6M
AVEM0.23%6.2M
EIMI.L0.11%4.8M
EIMU DE0.12%4.8M
VEU0.05%3.9M
EEM0.13%3.6M
MCHI0.64%3.5M
3416.HK1.04%2.6M

Analyst track record

How the analysts covering INNOVENT have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings00
Analysts00
Buy / hold / sell––
Upgrades / downgrades / initiations0 / 0 / 00 / 0 / 0
Price targets hit / missed––
Avg. return after a rating (TipRanks)––
Best / worst call– / –– / –

After buy calls on this stock: not enough measured cases yet

TipRanks data · computed Nov 11, 2026 · 0 ratings

Frequently asked questions

Where can I trade INNOVENT perpetual futures?

Innovent Biologics, Inc. (INNOVENT) perpetual futures trade on one crypto venue: MEXC. PerpEquities shows its live price, funding rate, open interest and liquidity.

Can I trade INNOVENT around the clock?

Yes. Unlike the underlying stock, INNOVENT perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on INNOVENT perpetuals?

Right now the INNOVENT perp funding rate is -21.9% annualized (one venue). A positive rate means longs pay shorts. PerpEquities shows the live rate and its history.

How does the INNOVENT perp price compare to the Innovent Biologics, Inc. stock?

The venue-median INNOVENT perp mark is $10.8 versus a reference stock price of $10.8, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a INNOVENT perpetual future?

A INNOVENT perpetual is a derivative that tracks the price of Innovent Biologics, Inc. with no expiry date. It lets you take long or short exposure to Innovent Biologics, Inc. on crypto venues, around the clock.

What is INNOVENTUSDT perpetual?

INNOVENTUSDT is the symbol most crypto exchanges use for the Innovent Biologics, Inc. perpetual settled in USDT (Tether). It tracks the INNOVENT share price through an index, trades 24/7 with leverage and never expires.

Also listed on MEXC

Embed this asset

INNOVENT perpetuals · perpequities.comINNOVENT perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/innovent-perp"><img src="https://perpequities.com/badge/innovent-perp.svg" width="240" height="64" alt="INNOVENT perpetuals · perpequities.com" loading="lazy"></a>

Raw data: JSON · CSV · API

Next step

Stay on top of INNOVENT perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for INNOVENT — one email every Sunday.

Watchlist and alerts

Price and funding alerts for INNOVENT, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X